Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

July 01, 2022; Volume 102,Issue 1

Articles

  • You have access
    Physiologic Targets and Modes of Action for CBL0137, a Lead for Human African Trypanosomiasis Drug Development
    Carlos E. Sanz-Rodríguez, Benjamin Hoffman, Paul J. Guyett, Andrei Purmal, Baljinder Singh, Michael P. Pollastri and Kojo Mensa-Wilmot
    Molecular Pharmacology July 2022, 102 (1) 1-16; DOI: https://doi.org/10.1124/molpharm.121.000430
  • You have access
    Discovery of Novel Activators of Large-Conductance Calcium-Activated Potassium Channels for the Treatment of Cerebellar Ataxia
    Sharan R. Srinivasan, Haoran Huang, Wei-Chih Chang, Joshua A. Nasburg, Hai M. Nguyen, Tim Strassmaier, Heike Wulff and Vikram G. Shakkottai
    Molecular Pharmacology July 2022, 102 (1) 17-28; DOI: https://doi.org/10.1124/molpharm.121.000478
  • You have access
    GPR83 Engages Endogenous Peptides from Two Distinct Precursors to Elicit Differential Signaling
    Seshat M. Mack, Ivone Gomes, Amanda K. Fakira, Mariana Lemos Duarte, Achla Gupta, Lloyd Fricker and Lakshmi A. Devi
    Molecular Pharmacology July 2022, 102 (1) 29-38; DOI: https://doi.org/10.1124/molpharm.122.000487

Special Section on Cardiometabolic Diseases: At the Crossroads of Adipose Tissue and the Heart

  • Open Access
    The Heartwarming Effect of Brown Adipose Tissue
    Kelsey M. Pinckard and Kristin I. Stanford
    Molecular Pharmacology July 2022, 102 (1) 39-50; DOI: https://doi.org/10.1124/molpharm.121.000328
  • You have access
    Calcium Cycling as a Mediator of Thermogenic Metabolism in Adipose Tissue
    Adrienne R. Guarnieri, Tyler W. Benson and Michael Tranter
    Molecular Pharmacology July 2022, 102 (1) 51-59; DOI: https://doi.org/10.1124/molpharm.121.000465
  • Sex Differences in Cardiovascular Impact of Early Metabolic Impairment: Interplay between Dysbiosis and Adipose Inflammation
    You have access
    Sex Differences in Cardiovascular Impact of Early Metabolic Impairment: Interplay between Dysbiosis and Adipose Inflammation
    Haneen S. Dwaib, Ibrahim AlZaim, Ghina Ajouz, Ali H. Eid and Ahmed El-Yazbi
    Molecular Pharmacology July 2022, 102 (1) 60-79; DOI: https://doi.org/10.1124/molpharm.121.000338
Back to top
PreviousNext

In this issue

Molecular Pharmacology: 102 (1)
Molecular Pharmacology
Vol. 102, Issue 1
1 Jul 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Articles
  • Special Section on Cardiometabolic Diseases: At the Crossroads of Adipose Tissue and the Heart
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics